Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989, enacted by the Australian Parliament, was introduced to regulate the supply, manufacture and advertising of therapeutic goods in Australia, aiming to ensure that these goods are of an acceptable quality, safety and efficacy. This legislation addresses the need to protect public health by ensuring that only safe and effective therapeutic goods are available to the Australian community. The Act establishes a licensing regime for the manufacture and importation of therapeutic goods, ensuring that only those entities meeting the regulatory standards can operate within the market. The policy objective of the Act is to safeguard public health by maintaining rigorous standards for therapeutic goods, thereby preventing the distribution and use of products that could potentially harm consumers. The Therapeutic Goods Administration, as a delegate of the Secretary of the Department of Health, publishes details concerning the grant of a licence to manufacture therapeutic goods. This specific publication lists entities that have been granted a licence, providing transparency and ensuring compliance with the regulatory framework established under the Act. The entities listed include SOUTH WESTERN SYDNEY LOCAL HEALTH DISTRICT, STERITECH PTY LTD, MEDIPHARM LABS AUSTRALIA PTY LTD, SURGICAL BIOFIX LTD, and THE KIRBY INSTITUTE - UNSW MEDICINE, each granted specific licences to manufacture therapeutic goods under the Act. This process underscores the commitment to maintaining high standards in the production of therapeutic goods, ultimately protecting public health.

Scope and Application

The Therapeutic Goods Act 1989 applies to a broad range of entities involved in the manufacture, supply, and advertising of therapeutic goods within Australia. The Act primarily applies to manufacturers, importers, and suppliers of therapeutic goods, including medicines, medical devices, blood, and tissues. These entities must comply with regulatory requirements to ensure the safety, quality, and efficacy of therapeutic goods available in the market. The legislation encompasses activities such as the manufacture, evaluation, and distribution of therapeutic goods, ensuring that all products meet stringent standards before reaching consumers. The Act’s jurisdictional reach is nationwide, impacting all states and territories within the Commonwealth of Australia, thereby unifying the regulatory framework across the country. Notably, the Act excludes certain goods, such as therapeutic goods used solely for personal, non-commercial purposes, from its scope. Additionally, the application and enforcement of the Act can be extended or modified through subordinate instruments, such as regulations and guidelines issued by the Therapeutic Goods Administration, which provide further detail and operational clarity to the overarching provisions of the Act.

Key Provisions

The main operative sections of the Therapeutic Goods Act 1989, as referenced in the Gazette, pertain to the granting of a licence to manufacture therapeutic goods. Specifically, section 38 of the Act allows the Secretary of the Department of Health, Therapeutic Goods Administration to issue licences to entities that meet the necessary standards for manufacturing therapeutic goods (section 38). This licence is essential for entities to legally manufacture therapeutic goods within Australia. The Therapeutic Goods Act 1989 imposes several obligations on the parties granted a licence to manufacture therapeutic goods. These obligations include maintaining manufacturing processes that adhere to Good Manufacturing Practice (GMP) standards, ensuring the quality and safety of the therapeutic goods produced, and complying with any specific conditions outlined in their licence. Additionally, licensed manufacturers must submit regular reports to the Therapeutic Goods Administration, detailing their manufacturing activities and any changes to their processes or facilities (section 38). Failure to comply with the requirements of the Therapeutic Goods Act 1989 can lead to various offences and penalties. For example, manufacturing therapeutic goods without a valid licence is an offence under the Act and can result in substantial penalties. The maximum penalties for such offences include fines up to $2,200,000 for corporations and up to $440,000 for individuals, as well as potential imprisonment terms. Additionally, the Therapeutic Goods Administration has the authority to cancel a licence if it is found that the manufacturer has breached the conditions of their licence or failed to meet the required standards. Such actions can have significant consequences for the entities involved, including the potential loss of their ability to manufacture therapeutic goods.